GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022:
A copy of the presentation materials will be accessible on the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Altimmune Investor & Media Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com
By Hari Prasad, Founder and CEO of Yosi Health Hari Prasad In today's digital age,…
OVERLAND PARK, Kan.--(BUSINESS WIRE)--#Interoperability--Netsmart, a leading provider of healthcare technology solutions and services for community-based…
OVERLAND PARK, Kan.--(BUSINESS WIRE)--#Interoperability--Netsmart, a leading provider of healthcare technology solutions and services for community-based…
Innovaccer integrates its Provider Copilot with athenahealth EHR to automate clinical documentation, generate potential diagnoses,…
London, United Kingdom--(Newsfile Corp. - July 11, 2024) - Edison issues report on Custodian Property…
London, United Kingdom--(Newsfile Corp. - July 11, 2024) - Edison issues report on Custodian Property…